- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07575698
The Effect of Seed Cycling-Based Nutritional Intervention on Premenstrual Symptoms
Evaluation of the Effect of Seed Cycling on Premenstrual Symptoms in Healthy Adults
This study aims to investigate the effects of the seed-cycling intervention on premenstrual symptoms and nutritional status. At the beginning of the study, written informed consent will be obtained from all individuals who agree to participate.
During the month prior to the intervention, participants' menstrual cycles will be monitored to determine their menstrual phases. In this period, dietary intake records and menstrual symptoms will be documented, and the estimated ovulation date will be determined based on reported symptoms.
After identifying the participants' follicular phase (approximately days 1-14) and luteal phase (approximately days 15-28), the intervention will be implemented for three consecutive months. Participants will be instructed to consume flaxseed and pumpkin seeds daily during the follicular phase, and sesame seeds and sunflower seeds daily during the luteal phase.
The oilseeds to be consumed will be provided to the participants at the beginning of each month in vacuum-sealed single-use packages.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
MELİKGAZİ
-
Kayseri, MELİKGAZİ, Türkei (türkiye)
- Erciyes University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria: Individuals aged 18-35 years, with a regular menstrual cycle, a body mass index (BMI) between 18.5 and 24.9 kg/m², who agreed to consume oilseeds for three menstrual cycles, and who are literate with no problems in Turkish communication or comprehension were included in the study.
-
Exclusion Criteria: Individuals were excluded if they were pregnant, lactating, or postmenopausal; had acute, chronic, or psychiatric disorders including hormonally diagnosed conditions such as PCOS that could affect menstruation; were receiving medications affecting hormones or menstrual cycles; were taking vitamin, mineral, or nutraceutical supplements; had allergies or intolerances to flaxseed, sunflower seeds, pumpkin seeds, or sesame; were positive for HIV or HPV infection; consumed alcohol regularly; or were following a special diet.
-
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assessment of Premenstrual Syndrome Scale at the beginning and End of the Study
Zeitfenster: The premenstrual weeks of the first and fourth months of the study
|
To evaluate the severity of symptoms experienced during the premenstrual period, the Premenstrual Syndrome Scale, a validated instrument, will be administered during the premenstrual weeks of the first and fourth months. The Premenstrual Syndrome Scale is a self-report measure developed to assess the physical, emotional, and behavioral symptoms experienced by women during the luteal phase of the menstrual cycle. The scale consists of a total of 44 items and comprises nine subdimensions. Each item is rated on a five-point Likert scale. Higher total scores obtained from the scale indicate greater severity of premenstrual symptoms. Subdimension scores may be calculated separately, and an overall assessment can also be conducted based on the total score. |
The premenstrual weeks of the first and fourth months of the study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assessment of Dietary Diversity Score at the Beginning and End of the Study
Zeitfenster: At the beginning of the first month and at the end of the fourth month of the study
|
The Dietary Diversity Score is based on the nine food groups recommended by the Food and Agriculture Organization.
According to the scoring system, a score of ≥6 points is classified as high dietary diversity, 4-5 points as moderate dietary diversity, and ≤3 points as low dietary diversity.
|
At the beginning of the first month and at the end of the fourth month of the study
|
|
Assessment of Composite Dietary Antioxidant Index at the Beginning and End of the Study
Zeitfenster: At the beginning of the first month and at the end of the fourth month of the study
|
The Composite Dietary Antioxidant Index (CDAI) is a quantitative measure that reflects the overall impact of the major antioxidant nutrients consumed through the diet and is used to assess the total antioxidant capacity of the diet.
This index is considered a reliable indicator as it represents the cumulative effect of dietary antioxidants.The Composite Dietary Antioxidant Index will be calculated based on individuals' 24-hour dietary intake records, by assessing the intake of six antioxidant nutrients: vitamin A, vitamin C, vitamin E, carotenoids, zinc, and selenium.
|
At the beginning of the first month and at the end of the fourth month of the study
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: ARMAĞAN AYTUĞ YÜRÜK, Principal Investigator, TC Erciyes University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026/127
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Prämenstruelles Syndrom-PMS
-
Haleema SadiaAbgeschlossenPrämenstruelles Syndrom-PMSPakistan
-
Esra ÖZERKTO Karatay UniversityAbgeschlossenPrämenstruelles Syndrom-PMSTruthahn
-
University of Health Sciences LahoreAktiv, nicht rekrutierendPrämenstruelles Syndrom-PMSPakistan
-
Shaare Zedek Medical CenterUnbekanntPrämenstruelles Syndrom-PMS
-
Aydin Adnan Menderes UniversityErzurum Technical UniversityAbgeschlossenEmotionsregulation | Prämenstruelles Syndrom-PMSTruthahn
-
Friederike HolzeNoch keine Rekrutierung
-
University of PennsylvaniaForest LaboratoriesBeendetPMSVereinigte Staaten
-
Universiti Tunku Abdul RahmanAbgeschlossen
-
Terra Biological LLCAbgeschlossenPrämenstruelles Syndrom (PMS)
-
Activ'insideAktiv, nicht rekrutierendPrämenstruelles Syndrom-PMSItalien
Klinische Studien zur Seed consumption
-
The University of Hong KongEndomagnetics Ltd.RekrutierungNeoplasma der Brust | Chemotherapie-EffektHongkong
-
Hopital FochAbgeschlossen
-
Beth Israel Deaconess Medical CenterSeed HealthAbgeschlossen
-
L.V. Prasad Eye InstituteSEED Co. Ltd.Aktiv, nicht rekrutierend
-
Rigshospitalet, DenmarkAbgeschlossen
-
Chinese University of Hong KongAbgeschlossenEntwicklung, Kind | AchtsamkeitHongkong
-
Clarunis - Universitäres Bauchzentrum BaselAbgeschlossenLeberzirrhose | LeberkrebsSchweiz
-
Peking University Third HospitalRekrutierungBrustkrebs | Radioaktives Jod-125 Brachytherapie | 3D-Druck-Koplanar-Vorlage | Nukleare StrahlungseffekteChina
-
Peking University Third HospitalRekrutierungPlattenepithelkarzinome | BrachytherapieChina
-
McMaster UniversityCanadian Breast Cancer FoundationAbgeschlossenInvasive Brustkrebs-Nr | Brustkrebs im Stadium 0Kanada